Preview

Современная ревматология

Расширенный поиск

Золедроновая кислота в лечении остеопороза: показания для назначения

https://doi.org/10.14412/1996-7012-2011-673

Аннотация

Описан механизм действия бисфосфоната (БФ) третьего поколения - золедроновой кислоты (акласта), приведены данные рандомизированных клинических исследований, посвященных изучению эффективности и переносимости препарата. Сделан вывод о том, что золедроновая кислота, назначаемая внутривенно 1 раз в год, может быть препаратом выбора для увеличения приверженности больных лечению, особенно в условиях часто встречающейся у пожилых больных полифармации и когнитивных нарушений. Кроме того, препарат можно назначать женщинам в постменопаузе с целью профилактики ОП 1 раз в 2 года.

Литература

1. <div><p>Клинические рекомендации. Остеопороз. Диагностика, профилактика и лечение. Под ред. О.М. Лесняк, Л.И. Беневоленской. М.: ГЭОТАР-Медиа, 2008; 171 с.</p><p>Siris E.S., Harris S.T., Rosen C.J. et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006; 81: 1013-22.</p><p>Huybrechts K.F., Ishak K.J., Caro J.J. Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 2006; 38: 922-8.</p><p>Rogers M.J., Frith J.C., Luckman P. et al. Molecular mechanisms of action of bisphosphonates. Bone. 1999; 24(Suppl.): 73S-79S.</p><p>Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev 1998; 19: 80-100.</p><p>Green J.R., Rogers M.J. Pharmacologic profile of zoledronic acid: a highly potent inhibitor of bone resorption. Drug Dev Res 2002; 55: 210-24.</p><p>Black D.M., Delmas P.D., Eastell R. et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007; 356(18): 1809-22.</p><p>Eastell R., Lang T., Boonen S. et al. Effect of once-yearly zoledronic acid on the spine and hip as measured by quantitative computed tomography: results of the HORIZON Pivotal Fracture Trial. Osteoporos Int 2009; DOI 10.1007/s00198-009-1077-9</p><p>Black D., Reid I.R., Cauley J.A. et al. The Effect of 3 Versus 6 Years of Zoledronic Acid Treatment in Osteoporosis: a Randomized Extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 2010; 25 (Suppl. 1): 1070. Available at &lt;http://www.asbmr.org/Meetings/AnnualMeeting/A&gt; bstract10.aspx</p><p>Lyles K.W., Colon-Emeric C.S., Magaziner J.S. et al. Zoledronic Acid in Reducing Clinical Fracture and Mortality after Hip Fracture. N Engl J Med 2007; 357(18): 1799-809.</p><p>Colon-Emeric C., Kuchibhatla M., Pieper C. et al. The contribution of hip fracture to risk of subsequent fracture: data from two longitudinal studies. Osteoporos Int 2003; 14: 879-83.</p><p>National Osteoporosis Foundation: Advocacy News and Updates - America's Bone Health: The State of Osteoporosis and Low Bone Mass. Available at &lt;http://www.nof.org/advocacy/preva-&gt;lence/index.htm</p><p>Михайлов Е.Е., Беневоленская Л.И. Эпидемиология остеопороза и переломов. Рук-во по остеопорозу. Под ред. Л.И. Беневоленской. М.: БИНОМ, 2003; 10-53.</p><p>Jones G., Nguyen T., Sambrook P.N. et al. Symptomatic fracture incidence in elderly men and women: the Dubbo Osteoporosis Epidemiology Study (DOES). Osteoporos Int 1994; 4: 277-82.</p><p>Cooper C., Campion G., Melton L.J. III. Hip fractures in the elderly: a world-wide projection. Osteoporos Int 1992; 2: 285-9.</p><p>Center J.R., Nguyen T.V., Schneider D. et al. Mortality after all major types of osteoporotic fractures in men and women: an observational study. Lancet 1999; 76: 235-42.</p><p>Keibzac G., Beinart G.A., Perser K. et al. Undertreatment of osteoporosis in men with hip fracture. Arch Intern Med 2002; 162: 2217-22.</p><p>Forsen L., Sogaard A.J., Meyer H.E. et al. Survival after hip fracture: short- and long-term excess mortality according to age and gender. Osteoporos Int 1999; 10: 73-8.</p><p>Grisso J.A., Kelsey J.L., O'Brien L.A. et al. Risk factors for hip fracture in men. Hip Fracture Study Group. Am J Epidemiol 1997; 145: 786-93.</p><p>Eastell R., Boyle I.T., Compston J. et al. Management of male osteoporosis: report of UK Consensus Group. QJM 1998; 91: 71-6.</p><p>Selby P.L., Davies M., Adams J.E. Do men and women fracture bones at similar bone densities? Osteoporos Int 2000; 11: 153-7.</p><p>Orwoll E., Miller P.D., Adachi J.D. et al. Efficacy and safety of a once-yearly i.v. infusion of zoledronic acid 5 mg versus a once-weekly 70 mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, doubleblind, active-controlled study. J Bone Miner Res 2010; 25: 2239-50.</p><p>Reid D.M., Devogelaer J.P., Saag K. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid- induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 2009; 373: 1253-63.</p><p>McClung M., Miller P., Recknor C. et al. Zoledronic Acid for the Prevention of Bone Loss in Postmenopausal Women With Low Bone Mass A Randomized Controlled Trial. Obstet Gynecol 2009; 114: 999-1007</p><p>Pazianas M., Compston J., Huang C. L.H. Atrial Fibrillation and Bisphosphonate Therapy. J Bone Miner Res 2010; 25(1): 2-10.</p><p>Grbic J.T., Landesberg R., Lin S.Q. et al. Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial. J Am Dent Assoc 2008; 139(1): 32-40.</p></div><br />


Для цитирования:


Торопцова Н.В., Торопцова Н.В. Золедроновая кислота в лечении остеопороза: показания для назначения. Современная ревматология. 2011;5(2):71-76. https://doi.org/10.14412/1996-7012-2011-673

For citation:


Toroptsova N.V., Toroptsova N.V. Zoledronic acid in the treatment of osteoporosis: indications for use. Modern Rheumatology Journal. 2011;5(2):71-76. https://doi.org/10.14412/1996-7012-2011-673

Просмотров: 1739


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1996-7012 (Print)
ISSN 2310-158X (Online)